Literature DB >> 23553770

The inhibition of p85αPI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells.

Antonia Feola1, Annamaria Cimini, Francesca Migliucci, Rosamaria Iorio, Candida Zuchegna, Rodger Rothenberger, Letizia Cito, Antonio Porcellini, Gerhard Unteregger, Vincenzo Tombolini, Antonio Giordano, Marina Di Domenico.   

Abstract

Phosphoinositide 3-kinase proteins are composed by a catalytic p110 subunit and a regulatory p85 subunit. There are three classes of PI3K, named class I-III, on the bases of the protein domain constituting and determining their specificity. The first one is the best characterized and includes a number of key elements for the integration of different cellular signals. Regulatory p85 subunit shares with the catalytic p110 subunit, a N-terminal SH3 domain showing homology with the protein domain Rho-GTP-ase. After cell stimulation, all class I PI3Ks are recruited to the inner face of the plasma membrane, where they generate phosphatidylinositol-3,4,5-trisphosphate by direct phosphorylation of phosphatidylinositol-4,5-bisphosphate. All pathways trigger the control of different phenomena such as cell growth, proliferation, apoptosis, adhesion and migration through various downstream effectors. We have previously provided direct evidences that a Serine in position 83, adjacent to the N-terminal SH3 domain of regulatory subunit of PI3K, is a substrate of PKA. The aim of this work is to confirm the role of p85αPI3KSer83 in regulating cell proliferation, migration and invasion in prostate cancer cells LNCaP. To this purpose cells were transfected with mutant forms of p85, where Serine was replaced by Alanine, where phosphorylation is prevented, or Aspartic Acid, to mimic the phosphorylated residue. The findings of this study suggest that identifying a peptide mimicking the sequence adjacent to Ser 83 may be used to produce antibodies against this residue that can be proposed as usefool tool for prognosis by correlating phosphorylation at Ser83 with tumor stage.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  LnCap; PHOSPHORYLATION; PROSTATE CANCER; REGULATORY SUBUNIT p85

Mesh:

Substances:

Year:  2013        PMID: 23553770     DOI: 10.1002/jcb.24558

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

1.  Interaction between CD133 and PI3K-p85 promotes chemoresistance in gastric cancer cells.

Authors:  Shuzheng Song; Guoqing Pei; Yaqiong Du; Jugang Wu; Xiaochun Ni; Shoulian Wang; Bojian Jiang; Meng Luo; Jiwei Yu
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

2.  The p85 regulatory subunit of PI3K mediates cAMP-PKA and insulin biological effects on MCF-7 cell growth and motility.

Authors:  E Di Zazzo; A Feola; C Zuchegna; A Romano; C F Donini; S Bartollino; C Costagliola; R Frunzio; P Laccetti; M Di Domenico; A Porcellini
Journal:  ScientificWorldJournal       Date:  2014-07-09

3.  The role of PI3K-mediated AMPA receptor changes in post-conditioning of propofol in brain protection.

Authors:  Chenxu Wang; Ying Wei; Yuan Yuan; Yonghao Yu; Keliang Xie; Beibei Dong; Yuan Shi; Guolin Wang
Journal:  BMC Neurosci       Date:  2019-10-01       Impact factor: 3.288

Review 4.  The Crosstalk between Prostate Cancer and Microbiota Inflammation: Nutraceutical Products Are Useful to Balance This Interplay?

Authors:  Felice Crocetto; Mariarosaria Boccellino; Biagio Barone; Erika Di Zazzo; Antonella Sciarra; Giovanni Galasso; Giuliana Settembre; Lucio Quagliuolo; Ciro Imbimbo; Silvia Boffo; Italo Francesco Angelillo; Marina Di Domenico
Journal:  Nutrients       Date:  2020-08-31       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.